Copper Histidinate (1 brand name, 1 dosage form, 1 route)
Available dosage forms: POWDER.
Routes of administration: SUBCUTANEOUS.
Brand Names
- ZYCUBO
Indications and Usage
ZYCUBO is indicated for the treatment of Menkes disease in pediatric patients.
Contraindications
None.
Adverse Reactions
The following clinically significant adverse reactions are described elsewhere in the labeling: Copper Accumulation and Risk of Toxicity: Drug-Induced Kidney Injury, Liver Dysfunction, Hematological Abnormalities [see Warnings and Precautions (5.1)]
Mechanism of Action
Menkes disease is an X-linked recessive disorder caused by pathogenic variants in the copper transport ATPase encoded by ATP7A. Patients with Menkes disease have impaired absorption of copper from their diet, impaired transport of copper across the blood-brain barrier, and dysregulation of many copper-dependent enzymes. ZYCUBO is a bioavailable copper replacement therapy that is administered as a subcutaneous injection to bypass the impaired gastrointestinal absorption observed in patients with Menkes disease.